Scientific Board

Switzerland

Scientific Board

Switzerland

Time filter

Source Type

CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


Rezaeian A.,Scientific Board | Ghayour-Mobarhan M.,Biochemistry of Nutritional Research Center | Mazloum S.R.,Nursing and Midwifery School | Yavari M.,Educational Development Office | Jafari S.-A.,Mashhad University of Medical Sciences
Singapore Medical Journal | Year: 2014

INTRODUCTION Iron deficiency, associated with a decline in cognitive function, is the most common nutritional deficiency globally. The present study aimed to identify the impact of weekly iron supplements on the attention function of female students from a high school in North Khorasan Province, Iran.METHODS This was a blind, controlled, clinical trial study, involving 200 female students who were chosen using the stratified randomised sampling method. First, laboratory studies were performed to detect iron consumption limitations. Next, the 200 students were divided randomly and equally into case and control groups. The case group was treated with 50 mg of ferrous sulfate twice a week for 16 weeks. We compared both groups’ data on attention, iron status and erythrocyte indices. Questionnaires were used to collect demographic data, while clinical data was collected using complete blood count and Toulouse-Piéron tests. Data was analysed using descriptive statistics, as well as paired and independent t-tests.RESULTS The mean attention scores of the case and control groups were 104.8 ± 7.0 and 52.7 ± 9.6, respectively (p < 0.001). The mean haemoglobin levels of the two groups were 12.5 ± 0.9 and 11.2 ± 1.0, respectively (p < 0.001). Compared to the control group, the attention scores and haemoglobin concentrations of the case group were found to be improved by approximately 90% and 10%, respectively.CONCLUSION Oral iron supplements (50 mg twice a week for 16 weeks) were able to improve the attention span and haematologic indices of female high school students. © 2014, Singapore Medical Association. All rights reserved.


News Article | August 31, 2016
Site: phys.org

Because forest elephants are one the slowest reproducing mammals in the world, it will take almost a century for them to recover from the intense poaching they have suffered since 2002. Credit: Andrea Turkalo/WCS Because forest elephants are one the slowest reproducing mammals in the world, it will take almost a century for them to recover from the intense poaching they have suffered since 2002. Not only does it take more than two decades for female forest elephants to begin reproducing, but they also give birth only once every five to six years. The findings are from a first-ever study of forest elephant demography published Aug. 31 in the Journal of Applied Ecology. There are two species of elephants in Africa. Savannah elephants make up the majority across the continent, with smaller numbers of the more diminutive forest elephants restricted to tropical forests. Forest elephants have experienced serious poaching, driving an estimated population decline of 65 percent between 2002 and 2013 according to a study led by the Wildlife Conservation Society (WCS). Their reported low birth rates mean that it will take forest elephants at least 90 years to recover from these losses, according to researchers from the WCS, the Cornell Lab of Ornithology's Elephant Listening Project, Colorado State University, and Save the Elephants. The team used decades of intensive monitoring data that recorded births and deaths of the elephants using the Dzanga Bai in Central African Republic, part of the UNESCO World Heritage Sangha Trinational area. (Dzanga Bai translates roughly as "village of elephants.") "This work provides another critical piece of understanding regarding the dire conservation status of forest elephants," said the study's lead author Andrea Turkalo, WCS Associate Conservation Scientist, who over several decades collected the detailed data on the Dzanga elephants despite tough logistical challenges and political instability. Using data Turkalo collected from 1990 to 2013 during nearly daily visits to a mineral rich forest clearing, or bai, that attracts elephants and other wildlife, the authors were able to uncover the age at which the forest elephants had their first calves, the length of time between calves, and other behaviors. The team found that forest elephants begin breeding later and have much longer calving intervals than other elephants, which means the population takes much longer to increase. "Female forest elephants in the Dzanga population typically breed for the first time after 23 years of age, a markedly late age of maturity relative to other mammals," Turkalo said. "In contrast, Savannah elephants typically begin breeding at age 12. In addition, breeding female forest elephants only produced a calf once every five or six years, relative to the three- to four-year interval found for Savannah elephants." The authors believe that the low birth rate is due to the challenges of living in a tropical forest, where new plant growth is mostly limited to the canopy. Said Peter Wrege, a Behavioral Ecologist at the Cornell Lab of Ornithology's Elephant Listening Project: "While we think of tropical forests as incredibly productive areas, most production occurs in the high canopy inaccessible to ground-dwelling species. In addition, vegetation in tropical systems are laden with compounds to defend their leaves from herbivores, including elephants. This means accessing resources is challenging for terrestrial fauna." George Wittemyer, chair of the Scientific Board of Save the Elephants and a professor in Wildlife Conservation at Colorado State University, said the findings are essential to assessing the status of forest elephants and projecting population decline in the face of illegal killing. "Legislation regarding ivory trade must consider the collateral effects on forest elephants and the difficulties of protecting them," Wittemyer said. "Trade in ivory in one nation can influence the pressures on elephants in other nations." The paper's findings show that the forest elephant is particularly susceptible to poaching - vital information in the push to close domestic ivory markets, which will be debated at the IUCN World Conservation Congress, which runs from Sept. 1-10 in Hawaii, and the Convention on International Trade in Endangered Species, which meets in Johannesburg in late September. The authors also highlight the importance of the results for interpreting carcass data collected through the Monitoring of Illegal Killing of Elephants program, which has shown high levels of poaching across central Africa. "Only by understanding the basic biology of forest elephants and other species, can we properly determine the level of threats they face from human activities," said Wittemyer. Forest elephants have critical ecological roles in these forests, and many tree species rely on the elephants to disperse their seeds. Continued decline in forest elephant numbers and range is likely to drive severe changes to these ecosystems, making their conservation status a significant global issue. Failing to protect forest elephants would also damage Central African forests, which are important for absorbing climate change gases. Explore further: At least 26 elephants massacred by C.African poachers


News Article | October 28, 2016
Site: www.marketwired.com

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes VANCOUVER, BC and BOSTON, MA--(Marketwired - October 27, 2016) - Imagin Medical ( : IME) ( : IMEXF) ( : DPD2) (the "Company") announced today that Dr. Liam J. Hurley, a member of the Northeast Urologic Surgery, PC, has joined Imagin's Scientific Board of Advisors. Dr. Hurley obtained his Bachelor of Arts degree from Harvard University and his M.D. from Boston University School of Medicine. After spending three years in the U.S. Navy, he completed a General Surgery Residency at St. Elizabeth's Medical Center of Boston and his Urology Residency at the Lahey Clinic in Burlington, MA. He is trained as an adult and pediatric urologist with expertise in genitourinary oncology. Dr. Hurley is a private practice community urologist who has clinical affiliations with Tufts New England Medical Center and Lahey Clinic. Other accomplishments include launching The Boston Urologic Society, serving on the Executive Committee for the Massachusetts Association of Practicing Urologists, and presiding as the Eastern Massachusetts representative to the New England Section of the AUA. Dr. Hurley is Board certified in Urology and is a Fellow of the American College of Surgeons. In 2006, he was chosen as one of Boston's "TOP DOCTORS" by Boston Magazine. "Dr. Hurley's knowledge and expertise in the urology field will be a great asset to our Advisory Board," said Jim Hutchens, Imagin President and CEO. "We look forward to his joining our team as we continue to add relevant expertise to help Imagin succeed." About Imagin Medical Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com. ON BEHALF OF THE BOARD: Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.


News Article | December 14, 2016
Site: globenewswire.com

AMSTERDAM, Netherlands, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Sustainalytics, a leading global provider of ESG and corporate governance research and ratings, today launched ESG Signals, an innovative quantitative tool that provides securities-level financial risk and opportunity signals based on environmental, social and governance (ESG), trading and financial data. ESG Signals analyzes thousands of correlations between variables over time and applies machine learning to extract meaningfully predictive risk/opportunity signals. Sustainalytics developed ESG Signals in collaboration with Advestis, a FinTech company that specializes in machine learning and big data techniques for asset management firms. ESG Signals combines seven years of Sustainalytics’ ESG research on more than 1,600 companies with trading and financial data from Advestis to provide heads of research and portfolio managers with a portfolio monitoring, alerting and investment decision support tool.  In addition, asset managers and index providers can use ESG Signals to develop new products. For every portfolio security, ESG Signals delivers either an opportunity, neutral or risk signal output. To test the findings, Sustainalytics and Advestis applied ESG Signals to a large cap, market weighted index. The index was adjusted to apply three ESG strategies: normative exclusion, best-in-class selection and a combination of the two. The reweighted indices outperformed the benchmark between 110 and 430 basis points annually, depending on the frequency of rebalancing adopted. “For almost 25 years, Sustainalytics has been at the forefront of supporting ESG-related investment strategies,” said Sustainalytics’ President and Chief Operating Officer, Bob Mann. “ESG Signals further underscores our commitment to innovation by exploiting big data techniques, quantitative modeling and machine learning to examine the links between ESG and financial performance factors. Our goal is to help investment managers identify and leverage ESG indicators with the most meaningful predictive value.” To date, ESG integration strategies have been largely qualitative in nature, primarily implemented as part of a qualitative process for risk mitigation.  As ESG factors become increasingly important considerations among mainstream investors, asset managers are looking for investment tools that have the ability to consistently and algorithmically analyze performance-based correlations to identify the most influent variables and in what circumstances they are most influent. “ESG variables provide additional information not fully captured by today’s financial or trading variables,” said Advestis’ CEO Christoph Geissler. “Leveraging Sustainalytics’ high quality research and extensive ESG experience provides investors with a more comprehensive picture of a portfolio company’s risks and opportunities. We are glad to be partnering with  Sustainalytics to develop ESG Signals and applaud them for their commitment to product innovation.” For more information on ESG Signals, please visit here. About Sustainalytics Sustainalytics is an independent ESG and corporate governance research, ratings and analysis firm supporting investors around the world with the development and implementation of responsible investment strategies. With 14 offices globally, Sustainalytics partners with institutional investors who integrate environmental, social and governance information and assessments into their investment processes. Today, the firm has more than 300 staff members, including 170 analysts with varied multidisciplinary expertise of more than 40 sectors. Through the IRRI survey, investors selected Sustainalytics as the best independent responsible investment research firm for three consecutive years, 2012 through 2014 and in 2015, Sustainalytics was named among the top three firms for both ESG and Corporate Governance research.  For more information, visit www.sustainalytics.com. About Advestis Advestis is a Paris-based FinTech that specializes in machine learning and big data techniques for asset management firms. Founded in 2011 by Christopher Geissler, Advestis employs four full-time professionals and is backed by three senior members of its Scientific Advisory board. Geissler is a financial data scientist with more than 30 years of experience in quantitative finance and machine learning. The firm invests more than 75 percent of its revenues in research and development, and has been awarded the ‘Innovating Fintech’ label by Finance Innovation for its work with Sustainalytics on ESG Signals. Advestis’ capital is owned primarily by the founder, members of its Scientific Board, and Quinten, a Paris-based data science company operating primarily in the healthcare and insurance sectors. For more information, visit www.advestis.com/en/. Disclaimer Nothing contained in this press release and tool shall be construed as to make a representation or warranty, express or implied, regarding the advisability to invest in or include companies in investable universes and/or portfolios. The performance represented is historical; past performance is not a reliable indicator of future results and results and the information provided in this press release and tool is not intended to be relied upon as, nor to be a substitute for specific professional advice and in particular financial advice. The information is provided “as is” and, therefore Sustainalytics assumes no responsibility for errors or omissions. Sustainalytics accepts no liability for damage arising from the use of press release, tool or information contained herein in any manner whatsoever.

Loading Scientific Board collaborators
Loading Scientific Board collaborators